Testing and Treating Mycobacterium tuberculosis Infection.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 36280337.
- Also identified by DOI 10.1016/j.mcna.2022.08.001.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
After infection with Mycobacterium tuberculosis, a minority of individuals will progress to tuberculosis disease (TB). The risk is higher among persons with well-established risk factors and within the first year after infection. Testing and treating individuals at high risk of progression maximizes the benefits of TB preventive therapy; avoiding testing of low-risk persons will limit potential harms. Several treatment options are available; rifamycin-based regimens offer the best efficacy-safety balance. In this review, we present an overview of the diagnosis and treatment of TB infection, and summarize common clinical scenarios.
Medical subject headings
- Tuberculosis
- Rifamycins